Percorrer por autor "Dias, Daniela"
A mostrar 1 - 7 de 7
Resultados por página
Opções de ordenação
- Antibiotic resistance in freshwater cyanobacteria and associated bacteriaPublication . Dias, Elsa; Dias, Daniela; Ferreira, Eugénia; Manageiro, Vera; Vasconcelos, Vitor; Pereira, Paulo; Caniça, ManuelaObjectives: Cyanobacteria are ubiquitous prokaryotes in aquatic ecosystems and although they can be exposed to antibiotics, their role on water resistome was never investigated. Thus, this work aimed to evaluate the antibiotic susceptibility patterns and resistance mechanisms of cyanobacteria and co-occurring bacteria in order to assess their contribution to the global pool of resistance determinants in freshwater. Methods: We investigated 4 cyanobacterial genera (Microcystis, Aphanizomenon, Anabaena and Planktothrix), previously isolated from freshwater reservoirs, and several bacteria isolated from those cyanobacterial cultures. Antibiotic susceptibility of cyanobacteria was evaluated by microdilution method, under specific culturing conditions, against beta-lactams, aminoglycosides, quinolones, sulfonamides and tetracyclines. Minimum inhibitory concentrations (MIC) were determined according to cyanobacterial cell dentisty (DO, 450nm) and microscopic examination of cultures integrity. Bacteria were identified by 16S sequencing and their susceptibility patterns were determined by disk diffusion, according to SFM 2012 non-specific breakpoints, against the same antibiotics. All strains were subjected to the search of class 1, 2 and 3 integrons and antibiotic resistance genes according to the phenotype. Results: Overall, we observed a great diversity of susceptibility to the tested antibiotics, among the distinct strains. Microcystis showed the lowest susceptibility regarding beta-lactams. Conversely, Microcystis was more susceptible to quinolones, while Planktothrix showed higher MIC values. Bacteria from cyanobacterial cultures were identified as Hydrogenophaga atypica, Limnobacter thioxidans, Rhizobium radiobacter, Sphingobium sp. and Brevundimonas lenta. Even though no known antibiotic resistance genes were yet identified, bacteria from different species and showing distinct phenotypes exhibited class 1 and 2 integrons. L. thioxidans, for example, revealed to be resistant to aminoglycosides and harbored a class 2 integron. Conclusions: Although no known antibiotic resistance genes were found in cyanobacteria and co-occurring bacteria, the presence of integrons and the susceptibility to antibiotics, suggest that they may play a role on freshwater resistome and eventually contribute to the dissemination of antibiotic resistance. These results may also be helpful to define guidelines and breakpoints to access cyanobacteria antibiotic susceptibility.
- COVID-19 Vaccine Effectiveness in Autumn and Winter 2022 to 2023 Among Older EuropeansPublication . Laniece Delaunay, Charlotte; Mazagatos, Clara; Martínez-Baz, Iván; Túri, Gergő; Goerlitz, Luise; Domegan, Lisa; Meijer, Adam; Rodrigues, Ana Paula; Sève, Noémie; Ilić, Maja; Latorre-Margalef, Neus; Lazar, Mihaela; Maurel, Marine; Melo, Aryse; Andreu Ivorra, Blanca; Casado, Itziar; Horváth, Judit Krisztina; Buda, Silke; Bennett, Charlene; de Lange, Marit; Guiomar, Raquel; Enouf, Vincent; Mlinarić, Ivan; Samuelsson Hagey, Tove; Dinu, Sorin; Rumayor, Mercedes; Castilla, Jesús; Oroszi, Beatrix; Dürrwald, Ralf; O’Donnell, Joan; Hooiveld, Mariëtte; Gómez, Verónica; Falchi, Alessandra; Kurečić Filipović, Sanja; Dillner, Lena; Popescu, Rodica; Bacci, Sabrina; Kaczmarek, Marlena; Kissling, Esther; Gallardo García, Virtudes; Perez Morilla, Esteban; Pedrosa Corral, Irene; García Vázquez, Miriam; Milagro-Beamonte, Ana; Fernandez Ibañez, Ana; Margolles Martins, Mario; Giménez Duran, Jaume; Sastre Palou, Bartolomé; López Causapé, Carla; Viloria Raymundo, Luis Javier; Vega Alonso, Tomás; Ordax Díez, Ana; Lozano Alonso, Jose Eugenio; Rojo Bello, Silvia; Mendioroz, Jacobo; Basile, Luca; Martínez Mateo, Ana Isabel; Ruiz de Porras, Carlota; Moya Garcés, Alba; Marcos, Mª Ángeles; López Maside, Aurora; Botella Quijal, Francesc; Miralles Espi, Maite; Andreu Salete, Cristina; García Rodríguez, María del Carmen; Linares, Juan Antonio; García Comas, Luis; Barranco, Mª Isabel; Chirlaque, María-Dolores; Moreno Docón, Antonio; Ramos Marín, Violeta; Castrillejo, Daniel; Gómez Anés, Atanasio; Larrauro, Amparo; Pérez-Gimeno, Gloria; Lozano Álvarez, Marcos; Vega, Lorena; Galindo, Silvia; Puma, Tania; Monge, Susana; Pozo, Francisco; Casas, Inmaculada; Sandonis, Virginia; Vázquez-Morón, Sonia; Echeverría, Aitziber; Trobajo-Sanmartín, Camino; García Cenoz, Manuel; Ezpeleta, Guillermo; Ezpeleta, Carmen; Navascués, Ana; Krisztalovics, Katalin; Mucsányiné Juhász, Krisztina; Kristóf, Katalin; Preuss, Ute; Wedde, Marianne; Biere, Barbara; Reiche, Janine; Oh, Djin-Ye; McKenna, Adele; Connell, Jeff; Joyce, Michael; Bagheri, Mariam; Bos, Sanne; van den Brink, Sharon; Dijkstra, Frederika; Eggink, Dirk; van Gageldonk-Lafeber, Rianne; Goderski, Gabriel; Herrebrugh, Chantal; Jenniskens, Liz; Reukers, Daphne; Sluimer, John; Sprong, Tara; Teirlinck, Anne; Veldhijzen, Nienke; van der Burgh, Ruben; Kager, Cathrien; Klinkhamer, Mayra; Knottnerus, Bart; Riethof, Marloes; van den Broek, Ruud; Wortel, Safira; Machado, Ausenda; Kislaya, Irina; Aniceto, Carlos; Gomes, Licínia; Verdasca, Nuno; Henriques, Camila; Dias, Daniela; Lança, Miguel; Blanchon, Thierry; Guerrisi, Caroline; Renard, Aubane; Launay, Titouan; Masse, Shirley; Chazelle, Marie; Ferenčak, Ivana; Kaić, Bernard; Višekruna Vučina, Vesna; Čusek Adamić, Katica; Kosanović Ličina, Mirjana Lana; Lakošeljac, Danijela; Mihin Huskić, Ivana; Nonković, Diana; Carnahan, Annasara; Hansson-Pihlainen, Eva; Arvesen, Elin; Nid, Nora; Hansen, Anna-Lena; Andersson, Emmi; Dillner, Lena; Jidovu, Adrian; Timnea, Olivia Carmen; Pascu, Cătălina; Oprea, Mihaela; Bistriceanu, Iulia; Ivanciuc, Alina; Mihai, Maria Elena; VEBIS Primary Care Vaccine Effectiveness GroupKey Points: - Question: What was the effectiveness of COVID-19 vaccines administered in autumn and winter 2022 to 2023 against symptomatic SARS-CoV-2 infection among people aged 60 years or older in Europe, and how did different exposed or reference groups affect effectiveness? - Findings: In this case-control study of 9308 primary care patients at 11 European sites, within 3 months of vaccination, all COVID-19 vaccine effectiveness (CVE) estimates were 29% to 39% against SARS-CoV-2 viruses and 44% to 52% against the XBB variants. All point estimates decreased by time after vaccination, with no vaccine protection after 6 months. - Meaning: Findings of this study suggest that COVID-19 vaccination campaigns should precede peaks in SARS-CoV-2 incidence and that effectiveness of new vaccines against emerging variants should be continually monitored using seasonal CVE approaches.
- Genetic and Epidemiological Insights Into Respiratory Syncytial Virus Infections: A Comparative Study of Hospitalized Versus Community Cases in Portugal (2021-2023)Publication . Lança, Miguel; Gaio, Vânia; Rodrigues, Ana Paula; Henriques, Camila; Gomes, Licínia; Dias, Daniela; Chasqueira, Maria de Jesus; Guiomar, Raquel; Melo, AryseBackground: Respiratory syncytial virus (RSV) is the leading cause of acute respiratory infection (ARI) in young children, but its genetic diversity requires ongoing surveillance. Methods: From 2021 to 2023, a total of 619 and 94 RSV-positive samples from the National Respiratory Syncytial Virus Surveillance Network (VigiRSV) and the Sentinel Influenza and other respiratory viruses surveillance network (Sentinel ISN), respectively, were analysed. The RSV A and RSV B typing was assessed by a multiplex real-time RT-PCR. Sanger sequencing was performed on a subset of samples (n = 495). Phylogenetic analysis was carried out on partial glycoprotein G sequences. Clinical and epidemiological data were compared through Pearson Chi-Square tests. Results: RSV Subgroup A was more prevalent (53.5%, 85/159) in the 2021/2022 season, whereas in the 2022/2023 season, it was RSV Subgroup B (82.1%, 435/530) in both networks. RSV A strains in VigiRSV clustered mainly to A.D.1 (39.0%, 39/100), whereas in Sentinel ISN, they clustered in A.D.5 (30.0%, 3/10). RSV Type B clustered mainly to B.D.E.1 (96.6%, 372/385) in both networks. All lineages cocirculated during the study period and in both surveillance networks. Regional clusters were identified for both subgroups. Conclusions: This study provides new insights into RSV genetic variability in Portugal, namely, the cocirculation of lineages and intravariability among lineages within both subgroups during the study period and in all Portuguese regions. However, our study is based on partial sequencing of the G gene, and because of this limitation, our results should be considered with great caution.
- Is it useful to ask "Está deprimido?" ("Are you depressed?") to terminally-ill Portuguese patients? Results from outpatient researchPublication . Julião, Miguel; Nunes, Baltazar; Sobral, Maria Ana; Dias, Daniela; Inocêncio, Inês; Barbosa, AntónioOBJECTIVES: Depression is a serious psychological problem in the palliative care setting. Brief screening tools for depression are lacking and need to be brief and acceptable. This study aimed to identify the properties of the single Portuguese question "Está deprimido?" ("Are you depressed?") to screen for depression. METHODS: Retrospective study from 100 patient's medical records identifying the answers on the single Portuguese question for depression "Está deprimido?" ("Are you depressed?") and the HADS depression sub-scale, using a score ≥11 on the latter as the gold standard for clinically significant depressive symptoms. Sensitivity, specificity, positive predictive and negative values were calculated. RESULTS: Response rate for the single Portuguese question for depression was 100%. Prevalence of depression symptoms (HADS-d ≥ 11) was 43%. To the question "Está deprimido?" 60 patients responded "yes." Sixteen patients who replied "no" to the single question had clinically significant depressive symptoms based on the HADS depression sub-scale. The single tool had 65.2% sensitivity, 49.2% specificity and 50.0% and 64.4% of positive predictive and negative values, respectively. SIGNIFICANCE OF RESULTS: In this first preliminary retrospective Portuguese study, the single question for depression has shown poor screening properties. Future research in larger and mixed patientś samples of Portuguese terminally ill is necessary to find more accurate and robust properties of this brief tool.
- Programa Nacional de Vigilância da Gripe: relatório da época 2022/2023Publication . Verdasca, Nuno; Melo, Aryse; Henriques, Camila; Gomes, Licínia; Lança, Miguel; Dias, Daniela; Silva, Susana Pereira da; Rodrigues, Ana Paula; Guiomar, Raquel; Direcção-Geral da Saúde (colaboração); Rede Portuguesa de Laboratórios para o Diagnóstico da Gripe e Outros Vírus Respiratórios (colaboração)Relatório anual do Programa Nacional de Vigilância da Gripe (PNVG). A presente publicação descreve a caraterização clínica e laboratorial da atividade gripal na época 2022/2023. O PNVG assegura a vigilância epidemiológica da gripe em Portugal, integrando as componentes de vigilância clínica e laboratorial. A componente clínica possibilita o cálculo de taxas de incidência permitindo descrever a intensidade e evolução da epidemia no tempo. A componente virológica tem por base o diagnóstico laboratorial do vírus da gripe, SARS-CoV-2 e vírus sincicial respiratório (RSV) o que permite detetar e caraterizar os vírus respiratórios em circulação em cada inverno. As atividades do PNVG são desenvolvidas pelo Laboratório Nacional de Referência para o Vírus da Gripe e Outros Vírus Respiratórios do Departamento de Doenças Infeciosas e pelo Departamento de Epidemiologia do Instituto Nacional de Saúde Doutor Ricardo Jorge, em colaboração com a Direção-Geral da Saúde. Da descrição da atividade gripal no inverno de 2022/2023 agora apresentada, destacam-se os seguintes resultados: - Na época 2022/2023 a atividade gripal foi de baixa intensidade, tendo sido verificada a epidemia de gripe mais precoce ocorrida nas últimas épocas; - O vírus da gripe A(H3) foi o predominante durante o período epidémico, tendo sido detetados em cocirculação os vírus da gripe A(H1)pdm09 e do tipo B; - A análise virológica demonstrou que os vírus da gripe circulantes eram na sua maioria semelhantes aos vírus que integraram a vacina de 2022/2023. A análise do genoma viral mostrou alguma diversidade genética nos vírus em circulação; - Os vírus SARS-CoV-2 pertenciam na sua maioria à linhagem BA.5 e XBB; - Foi nas crianças entre os 5 e os 14 anos que se detetou a maior percentagem de casos de gripe (33%), seguidas dos jovens e adultos entre os 15 e os 29 anos (26%); - Observou-se um excesso de mortalidade de cerca de 1959 óbitos, no período coincidente com a epidemia de gripe e de frio extremo; - A taxa de admissão de casos confirmados de gripe em UCI registou o valor máximo nas semanas 47/2022 e 10/2023. O vírus influenza tipo A foi identificado na quase totalidade dos casos. Os resultados obtidos no relatório constituem informação útil para a orientação e planeamento de medidas de prevenção e controlo da gripe, SARS-CoV-2, RSV e de outros vírus respiratórios de forma precisa.
- Programa Nacional de Vigilância da Gripe: relatório da época 2023/2024Publication . Guiomar, Raquel; Verdasca, Nuno; Gomes, Licínia; Henriques, Camila; Dias, Daniela; Lança, Miguel; Rodrigues, Ana Paula; Silva, Susana Pereira da; Direcção-Geral da Saúde (colaboração); Rede Portuguesa de Laboratórios para o Diagnóstico da Gripe e Outros Vírus Respiratórios (colaboração)Relatório anual do Programa Nacional de Vigilância da Gripe e de Outros Vírus Respiratórios (PNVG), que descreve a caraterização clínica e laboratorial da atividade gripal na época 2023/2024. O PNVG assegura a vigilância epidemiológica da gripe em Portugal, integrando as componentes de vigilância clínica e laboratorial. A componente clínica possibilita descrever a intensidade e evolução da epidemia no tempo. A componente virológica tem por base o diagnóstico laboratorial do vírus da gripe, SARS-CoV-2 e vírus sincicial respiratório (RSV) o que permite detetar e caraterizar os vírus respiratórios em circulação em cada inverno. As atividades do PNVG são desenvolvidas pelo Laboratório Nacional de Referência para o Vírus da Gripe e Outros Vírus Respiratórios do Departamento de Doenças Infeciosas e pelo Departamento de Epidemiologia do INSA, em colaboração com a Direção-Geral da Saúde.
- Vigilância do vírus sincicial respiratório em crianças menores de 2 anos em Portugal, 2022/23Publication . Guiomar, Raquel; Verdasca, Nuno; Melo, Aryse; Gomes, Licínia; Henriques, Camila; Dias, Daniela; Lança, Miguel; Torres, Ana Rita; Pernadas, Bernardo; Gaio, Vânia; Rodrigues, Ana PaulaO vírus sincicial respiratório (Respiratory Syncytial Virus - RSV) é um dos principais agentes etiológicos de infeções respiratórias do trato respiratório inferior, com elevado impacto na morbilidade e mortalidade em crianças menores de 5 anos. É por isso considerado um problema de saúde pública pela Organização Mundial de Saúde, com prioridade na vigilância e prevenção. Este trabalho pretende descrever e caraterizar os casos de infeção por RSV identificados no sistema de vigilância VigiRSV durante a época 2022/23.